OBJECTIVES: With the world population rapidly aging, it is increasingly important to identify sociodemographic, cognitive, and clinical features that predict poor outcome in geriatric depression. Self-report measures of resilience-ie, the ability to adapt and thrive in the face of adversity-may identify those depressed older adults with more favorable prognoses. METHODS: We investigated the utility of baseline variables including 4 factors of resilience (grit, active coping self-efficacy, accommodative coping self-efficacy, and spirituality) for predicting treatment response and remission in a 16-week randomized controlled trial of methylphenidate, citalopram, or their combination in 143 adults over the age of 60 with MDD. RESULTS: Final logistic regression models revealed that greater total baseline resilience (Wald χ2 = 3.8, P = 0.05) significantly predicted both treatment response and remission. Specifically, a 20% increase in total resilience predicted nearly 2 times greater likelihood of remission (OR = 1.98, 95% CI = [1.01, 3.91]). Examining the individual factors of resilience, only accommodative coping self-efficacy (Wald χ2 = 3.7, P = 0.05; OR = 1.41 [1.00-2.01]) was significantly associated with remission. We found no relation between baseline sociodemographic factors (age, sex, race, education level) or measures of cognitive performance and posttreatment depressive symptoms. CONCLUSIONS: Self-reported resilience may predict greater responsivity to antidepressant medication in older adults with MDD. Future research should investigate the potential for resilience training-and in particular, interventions designed to increase accommodative coping-to promote sustained remission of geriatric depression.
RCT Entities:
OBJECTIVES: With the world population rapidly aging, it is increasingly important to identify sociodemographic, cognitive, and clinical features that predict poor outcome in geriatric depression. Self-report measures of resilience-ie, the ability to adapt and thrive in the face of adversity-may identify those depressed older adults with more favorable prognoses. METHODS: We investigated the utility of baseline variables including 4 factors of resilience (grit, active coping self-efficacy, accommodative coping self-efficacy, and spirituality) for predicting treatment response and remission in a 16-week randomized controlled trial of methylphenidate, citalopram, or their combination in 143 adults over the age of 60 with MDD. RESULTS: Final logistic regression models revealed that greater total baseline resilience (Wald χ2 = 3.8, P = 0.05) significantly predicted both treatment response and remission. Specifically, a 20% increase in total resilience predicted nearly 2 times greater likelihood of remission (OR = 1.98, 95% CI = [1.01, 3.91]). Examining the individual factors of resilience, only accommodative coping self-efficacy (Wald χ2 = 3.7, P = 0.05; OR = 1.41 [1.00-2.01]) was significantly associated with remission. We found no relation between baseline sociodemographic factors (age, sex, race, education level) or measures of cognitive performance and posttreatment depressive symptoms. CONCLUSIONS: Self-reported resilience may predict greater responsivity to antidepressant medication in older adults with MDD. Future research should investigate the potential for resilience training-and in particular, interventions designed to increase accommodative coping-to promote sustained remission of geriatric depression.
Authors: George S Alexopoulos; Charles E Glatt; Matthew J Hoptman; Dora Kanellopoulos; Christopher F Murphy; Robert E Kelly; Sarah S Morimoto; Kelvin O Lim; Faith M Gunning Journal: J Affect Disord Date: 2010-03-25 Impact factor: 4.839
Authors: Victoria S Marshe; Malgorzata Maciukiewicz; Soham Rej; Arun K Tiwari; Etienne Sibille; Daniel M Blumberger; Jordan F Karp; Eric J Lenze; Charles F Reynolds; James L Kennedy; Benoit H Mulsant; Daniel J Müller Journal: Am J Psychiatry Date: 2017-01-10 Impact factor: 18.112
Authors: Sarah Shizuko Morimoto; Faith M Gunning; Dora Kanellopoulos; Christopher F Murphy; Sibel A Klimstra; Robert E Kelly; George S Alexopoulos Journal: Int J Geriatr Psychiatry Date: 2011-05-25 Impact factor: 3.485
Authors: Sarah Shizuko Morimoto; Faith M Gunning; Christopher F Murphy; Dora Kanellopoulos; Robert E Kelly; George S Alexopoulos Journal: Am J Geriatr Psychiatry Date: 2011-02 Impact factor: 4.105
Authors: F Andrew Kozel; Madhukar H Trivedi; Stephen R Wisniewski; Sachiko Miyahara; Mustafa M Husain; Maurizio Fava; Barry Lebowitz; Sidney Zisook; A John Rush Journal: Am J Geriatr Psychiatry Date: 2008-01 Impact factor: 4.105
Authors: Guy G Potter; Joshua D Kittinger; H Ryan Wagner; David C Steffens; K Ranga Rama Krishnan Journal: Neuropsychopharmacology Date: 2004-12 Impact factor: 7.853
Authors: Kelsey T Laird; Helen Lavretsky; Pattharee Paholpak; Roza M Vlasova; Michael Roman; Natalie St Cyr; Prabha Siddarth Journal: Int Psychogeriatr Date: 2018-01-16 Impact factor: 3.878
Authors: Grant L Iverson; Ryan Van Patten; Douglas P Terry; Christopher R Levi; Andrew J Gardner Journal: Front Neurol Date: 2021-04-01 Impact factor: 4.003